FreeStyle Libre 3 OK’d; P2 Win for Hypoparathyroidism Tx; Saxenda a ‘Vanity’ Drug?

The FDA cleared the next-generation FreeStyle Libre 3 system, a 14-day continuous glucose monitor for patients ages 4 and up, Abbott announced.

In other regulatory news, the FDA approved brolucizumab (Beovu) 6 mg for diabetic macular edema, Novartis announced. The treatment already holds an indication for wet age-related macular degeneration.

Among patients ages 66 and older, fragility fracture risk associated with the use of SGLT2 inhibitors wasn’t any different than with DPP-4 inhibitors. “This study reassures patients and doctors that SGLT-2 inhibitors are not associated with an increased risk of fracture in patients with chronic kidney disease,” said lead author Andrea Cowan, MD, of London Health Sciences Centre, in a statement. (CJASN)

Daily treatment with the investigational treatment AZP-3601 helped patients with hypoparathyroidism to discontinue standard of care therapy — oral calcium and active vitamin D supplementation — while maintaining mean serum calcium within target range in a phase IIa trial, Amolyt Pharma announced.

A study of Japanese adults with prediabetes found 0.75 μg per day of eldecalcitol, an analog of vitamin D, didn’t prevent the progression to type 2 diabetes. (BMJ)

Use of an interactive mobile app that tracks a child’s weight development in live time was more effective than standard of care in treating childhood obesity, a 1-year trial found. (International Journal of Obesity)

A 55-year old woman’s insurance company refused to cover the $1,500/month cost of liraglutide (Saxenda) after labeling the obesity medication as a “vanity drug.” (New York Times)

A mouse study found that type 1 diabetes was linked to weakened tooth enamel and dentine microhardness. (Archives of Oral Biology)

The Endocrine Society announced the five recipients of its Early Investigators Awards for 2022.